RRx-001: Jack of all trades, master of…many
Drug Discovery World
FEBRUARY 2, 2023
RRx-001 directly and irreversibly binds to a specific amino acid cysteine residue on a protein complex called the NLRP3 inflammasome, which serves as the “on switch” for inflammation. A late-stage clinical trial in head and neck cancer for the treatment of severe oral blistering or oral mucositis caused by radiation therapy is planned.
52 
Let's personalize your content